Brief: Interpace Diagnostics Changes Name To Interpace Biosciences, Announces Q3 Results

Interpace Biosciences

13/11/2019 22:14

Nov 13 (Reuters) - Interpace Biosciences Inc  IDXG.O :
    * INTERPACE DIAGNOSTICS CHANGES NAME TO INTERPACE
BIOSCIENCES;
ANNOUNCES PLANS FOR NEXT PHASE OF GROWTH AND THIRD QUARTER 2019
FINANCIAL RESULTS
    * Q3 LOSS PER SHARE $0.19
    * Q3 EARNINGS PER SHARE ESTIMATE $-0.19 -- REFINITIV IBES
DATA
    * SEES FY 2019 REVENUE $28 MILLION TO $32 MILLION
    * SEES FY 2020 REVENUE $50 MILLION
    * Q3 REVENUE $7.7 MILLION
    * Q3 REVENUE ESTIMATE $10.5 MILLION -- REFINITIV IBES DATA
    * ACQUIRED BIOPHARMA BUSINESS IN PARTNERSHIP WITH AMPERSAND
    * CONFIRMING TOP-LINE REVENUE GUIDANCE OF $50 MILLION FOR
2020.
    * INTERPACE BIOSCIENCES WILL CONTINUE TO TRADE ON NASDAQ AS
IDXG.

Source text for Eikon:  ID:nGNXbSvBK6 
Further company coverage:  IDXG.O 

 ((Reuters.Briefs@thomsonreuters.com;))